Cytokinetics analyst coverage

Author: zsnb

August undefined, 2024

WebMar 7, 2024 · Cytokinetics (CYTK) Analysts Prediction, Stock Forecast & Price Targets - Simply Wall St View Valuation Cytokinetics Future Growth Future criteria checks 0/6 Cytokinetics, Incorporated's earnings is forecasted to decline at 23.5% and its revenue is expected to decline at 46.6%. WebMar 31, 2024 · SOUTH SAN FRANCISCO, Calif., March 31, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring …

Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv

WebShare This: Share 2024 – Summer Analyst Internship – Financial Institutions Coverage (FIC) on Facebook Share 2024 – Summer Analyst Internship – Financial Institutions ... Financial Institutions Coverage (FIC) manages relationships with the bank’s largest institutional clients across key sectors: banks, hedge funds, asset managers ... WebOur Corporate Responsibility Framework. Keep Patients at the Center of our Work. Continue to embed patient centricity across all stages of our business. Maintain strong … diary of edward bates

ANALYST COVERAGE Cytokinetics, Inc.

WebMar 3, 2024 · Following the latest upgrade, the current consensus, from the 13 analysts covering Cytokinetics, is for revenues of US$54m in 2024, which would reflect a stressful 43% reduction in... WebFintel reports that on April 13, 2024, Baird initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with a Outperform recommendation. Analyst Price Forecast Suggests 80.40% Upside As of April 6 ... WebApr 5, 2024 · Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. INVESTORS & … cities skylines steam family sharing

Industry Analysts Just Upgraded Their Cytokinetics, Incorporated ...

WebApr 9, 2024 · Truist Financial initiated coverage on shares of Cytokinetics in a research note on Tuesday, December 20th. They issued a “buy” rating and a $60.00 target price for the company. Bank of America... WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media. ... Analyst Coverage. Investor FAQ. IR/Media Contacts. Corporate Governance. Information Request . Email Alerts . cities skylines steam idWebCYTK Stock 12 Months Forecast. $58.50. (66.24% Upside) Based on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $58.50 with a high forecast of $80.00 and a low forecast of $42.00. The average price target represents a 66.24% change from the last price of $35.19. diary of egeria

"WebApr 12, 2024 · Wall Street Analyst Weigh In. Several brokerages recently weighed in on CYTK. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a ... " - Cytokinetics analyst coverage

Cytokinetics analyst coverage

Cytokinetics Announces COURAGE-ALS Met Criteria for …

WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class … WebApr 9, 2024 · CYTK has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a research note on ...

Did you know?

WebPer-Share Earnings, Actuals & Estimates Cytokinetics Inc. Quarterly Annual Actual Analyst Range Consensus 0.50 0.00 -0.50 -1.00 -1.50 CYTK will report Q1 earnings on … WebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth …

WebCytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. Stock Information Press Releases WebOct 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential...

WebApr 6, 2024 · Analyst Price Forecast Suggests 12.99% Upside As of April 6, 2024, the average one-year price target for Broadcom is $696.81. The forecasts range from a low of $589.84 to a high of $787.50. WebJan 7, 2024 · Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten; Royalty Pharma Purchases Royalties on Future Sales of Aficamten; Cytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET; NEW YORK, NY and SOUTH SAN FRANCISCO, …

WebApr 11, 2024 · What analysts cover Cytokinetics? Cytokinetics has been rated by Bank of America, Cantor Fitzgerald, HC Wainwright, JMP Securities, Mizuho, Needham & Company LLC, Oppenheimer, The Goldman Sachs Group, and UBS Group in the past 90 days. Stock Ratings Reports and Tools Top-Rated Brokerages Stock Ratings Screener Free Ratings …

WebJul 19, 2024 · The webcast can be accessed through the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) ( United States and Canada ) or (706) 679-3078 (international) and typing in the passcode 2984784. diary of ebay pirateWeb17 rows · ANALYST COVERAGE. Cytokinetics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Cytokinetics, Inc. 's performance made by these analysts are theirs alone and do not represent opinions, … cities skylines steam keyboard shortcutsWebMar 7, 2024 · Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Mizuho Posted by Defense World Staff on Mar 7th, 2024 Mizuho assumed coverage on shares of Cytokinetics ( NASDAQ:CYTK – Get... cities skylines steam key freeWebOct 7, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. cities skylines steam mod monumentsWebMay 24, 2024 · Below is a summary of how these 4 analysts rated Cytokinetics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … diary of elizabeth kindelmannWebApr 2, 2024 · Financials. In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same periods of 2024. This ... cities skylines steam key cheapWebSep 28, 2024 · News Profile Analyst Coverage 5 Yr. Financials Dividends Adv. Charts Earnings Options Price History Events Insiders diary of elizabeth drinker